国产长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床研究  

Clinical research on combined chemotherapy of vinorelbine and cisplatin in the treatment of non-small cell lung cancer

作　　者：方浩徽 牛华[1] 郝红星[1] 

机构地区：[1]安徽省肺科医院呼吸内科,合肥230022

出　　处：《安徽医学》2007年第3期187-189,共3页Anhui Medical Journal

摘　　要：目的 观察国产长春瑞滨（NVB,盖诺）加顺铂（DDP）联合化疗治疗晚期非小细胞肺癌（NSCLC）的近期疗效、毒副反应、中位生存期及生存率.方法 对52例不宜或不能手术的Ⅲa～Ⅳ期非小细胞肺癌采用NVB联合DDP方案化疗,采用盖诺25 mg/m^2静脉推注,第1、8天,顺铂60～70 mg/m^2静脉滴注,分3～4天应用,28天为一个周期.结果 本组病例回顾性分析研究,其中PR18例（34.6%）,MR9例（17.3%）,SD17例（32.7%）,PD8例（15.4%）,临床获益率84.6%（44/52）;生存期为3～26个月,中位生存期为10.1个月,1年生存率为37.71%,2年生存率为17.24%;主要毒副反应为骨髓抑制,消化道反应.结论 本方案治疗晚期非小细胞肺癌的疗效较高、副反应较小、患者能够耐受的治疗方案.Objective To evaluate the efficacy, side - effects, median survival duration and sui＇vival rate of vinorelbine （NVB） combined with cisplatin（DDP） in the treatment of non - small cell Iung cancer （NSCLC）. Methods A total of 52 patients with inoperable NSCLC received NVB and DDP combined chemotherapy：/NVB 25 mg/m^2 on day 1 and 8, DDP 60 - 70 mg/m^2 on day 1 - 3, The scheduIe was repeated every 28 day. Results The overall response rate was 34.6%. The survival duration was 3 - 26 months, the median survival duration was 10.1 months. The 1 -and 2 -year survival rates was 37.71% and 17.24% ; The main side - effects ware myelosuppression and digestive. Conclusion Vinorelbine plus cisplatin is an effective and well - tolerated regimen for non - small cell lung cancer.

关 键 词：晚期非小细胞肺癌 化疗 长春瑞滨 顺铂 疗效 生存 

分 类 号：R734.2[医药卫生—肿瘤]